Wu Yudi, Liu Liang, He Fangxun, Zhang Yujie, Jiang Wei, Cao Zhixin, Xu Xiangshang, Gong Jianping
Department of Gastrointestinal Surgery, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, P.R. China.
GI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, P.R. China.
iScience. 2024 Jun 8;27(7):110228. doi: 10.1016/j.isci.2024.110228. eCollection 2024 Jul 19.
Colorectal cancer (CRC) is a prevalent cancer with intraperitoneal free cancer cells (IFCCs) playing a significant role in prognosis, especially during surgeries. The identification of IFCCs is crucial for determining the stage and treatment of patients with CRC. Existing methods for IFCC detection, such as conventional cytology, immunocytochemistry (ICC), and polymerase chain reaction (PCR), have limitations in sensitivity and specificity. This study investigates the potential of long noncoding RNA (lncRNA) SNHG1 as a biomarker for detecting IFCCs in patients with CRC. Testing on a cohort of 91 patients with CRC and 26 patients with gastrointestinal benign disease showed that SNHG1 outperformed CEA in distinguishing CRC cells and detecting IFCCs across different disease stages. SNHG1 demonstrated higher sensitivity (76.1% vs. 43.1%) and specificity (68.4% vs. 52.3%) than CEA for IFCC detection in patients with CRC, suggesting its promising role as a clinical method for identifying IFCCs in CRC.
结直肠癌（CRC）是一种常见的癌症，腹腔内游离癌细胞（IFCCs）在预后中起着重要作用，尤其是在手术期间。IFCCs的识别对于确定CRC患者的分期和治疗至关重要。现有的IFCC检测方法，如传统细胞学、免疫细胞化学（ICC）和聚合酶链反应（PCR），在灵敏度和特异性方面存在局限性。本研究调查了长链非编码RNA（lncRNA）SNHG1作为检测CRC患者IFCCs生物标志物的潜力。对91例CRC患者和26例胃肠道良性疾病患者的队列进行检测，结果显示，在区分CRC细胞和检测不同疾病阶段的IFCCs方面，SNHG1优于癌胚抗原（CEA）。在CRC患者中，SNHG1检测IFCCs的灵敏度（76.1%对43.1%）和特异性（68.4%对52.3%）均高于CEA，表明其作为识别CRC中IFCCs的临床方法具有广阔前景。
